How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Natural Killer Cells Therapeutics Market
- By Therapy Type: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Engagers, NK Cell-Derived Exosomes, CAR-NK Cell Therapy
- By Indication: Hematologic Malignancies, Solid Tumors, Viral Infections, Autoimmune Diseases, Graft-versus-Host Disease
- By Source of NK Cells: Peripheral Blood-Derived NK Cells, Umbilical Cord Blood-Derived NK Cells, Induced Pluripotent Stem Cell (iPSC)-Derived NK Cells, NK Cell Lines (e.g., NK-92)
- By Product Type: NK Cell Therapy Products, NK Cell Expansion and Activation Kits, NK Cell Engineering Platforms, NK Cell Delivery Systems
- By End User: Hospitals and Clinics, Research and Academic Institutes, Contract Research Organizations (CROs), Biopharmaceutical Companies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Autologous NK Cell Therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the Natural Killer Cells Therapeutics Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 5
Indication 5
Source of NK Cells 4
Product Type 4
End User 4
Companies profiled
Fate Therapeutics Inc.
Nkarta Therapeutics Inc.
Genocea Biosciences Inc.
Cellularity Inc.
Kiadis Pharma (Sanofi)
Gilead Sciences
Inc. (Kite Pharma)
ImmunityBio Inc.
Celyad Oncology SA
Dragonfly Therapeutics Inc.
Affimed N.V.
Artiva Biotherapeutics Inc.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Fate Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Nkarta Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Genocea Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Cellularity Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Kiadis Pharma (Sanofi)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Gilead Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Inc. (Kite Pharma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →ImmunityBio Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Celyad Oncology SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Dragonfly Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Affimed N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Artiva Biotherapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Cytovia Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Natural Killer Cell Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →CytoSen Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →OncoImmune
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,721M by 2033 · 8.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Autologous NK Cell Therapy34.6
- Allogeneic NK Cell Therapy21.4
- NK Cell Engagers17.2
- NK Cell-Derived Exosomes15.5
- CAR-NK Cell Therapy11.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,555M → $3,199M · 9.4%
Europe$1,084M → $2,021M · 8.1%
Asia Pacific$989.3M → $1,675M · 6.8%
Latin America$612.4M → $1,268M · 9.5%
Middle East and Africa$471.1M → $818.4M · 7.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.962026
7.962027
7.982028
7.992029
8.012030
8.022031
8.032032
8.042033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Fate Therapeutics Inc.22.0
- Nkarta Therapeutics Inc.17.5
- Genocea Biosciences Inc.4.5
- Cellularity Inc.8.9
- Kiadis Pharma (Sanofi)10.5
- Gilead Sciences8.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type18.3%
Indication15.8%
Source of NK Cells36.4%
Product Type12.1%
End User17.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.6
- Europe22.5
- Asia Pacific18.6
- Latin America14.1
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc. | 83 | 84 | 84 | 85 | 85 | 85 | 84 |
| Nkarta Therapeutics Inc. | 92 | 92 | 72 | 79 | 76 | 91 | 84 |
| Genocea Biosciences Inc. | 84 | 71 | 73 | 78 | 84 | 69 | 77 |
| Cellularity Inc. | 81 | 64 | 77 | 82 | 82 | 66 | 75 |
| Kiadis Pharma (Sanofi) | 64 | 68 | 70 | 61 | 62 | 63 | 65 |
| Gilead Sciences | 69 | 70 | 59 | 64 | 52 | 52 | 61 |
| Inc. (Kite Pharma) | 47 | 48 | 63 | 62 | 64 | 57 | 57 |
| ImmunityBio Inc. | 39 | 55 | 59 | 42 | 44 | 55 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Fate Therapeutics Inc.
- Nkarta Therapeutics Inc.
- Genocea Biosciences Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Fate Therapeutics Inc. | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Nkarta Therapeutics Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Genocea Biosciences Inc. | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Cellularity Inc. | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Kiadis Pharma (Sanofi) | ◐ | ◐ | ◐ | − | − | ◐ |
| Gilead Sciences | ✓ | ◐ | − | ◐ | ◐ | ◐ |
| Inc. (Kite Pharma) | − | − | ◐ | ◐ | − | ◐ |
| ImmunityBio Inc. | − | ◐ | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Fate Therapeutics Inc.84
2Nkarta Therapeutics Inc.84
3Genocea Biosciences Inc.77
4Cellularity Inc.75
5Kiadis Pharma (Sanofi)65
6Gilead Sciences61
7Inc. (Kite Pharma)57
8ImmunityBio Inc.49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Fate Therapeutics Inc.Nkarta Therapeutics Inc.
Challenger2
Strong scale, closing on the leaders.
Genocea Biosciences Inc.Cellularity Inc.
Contender3
Focused players with pockets of strength.
Kiadis Pharma (Sanofi)Gilead SciencesInc. (Kite Pharma)
Niche1
Specialists in a single segment or region.
ImmunityBio Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapy Type in North America, then scale across Natural Killer Cells Therapeutics Market — a $88M beachhead inside a $1.37B market.
Beachhead (SOM)$88Mobtainable near-term
Serviceable (SAM)$534Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Autologous NK Cell Therapy
Best fit — highest urgency & budget in Therapy Type.
Economic buyer77 fit
Allogeneic NK Cell Therapy
Strong fit — clear ROI and a fast path to value.
End user66 fit
NK Cell Engagers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Source of NK Cells
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel26%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Natural Killer Cells Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified21%
Evaluation12%
Closed-won8%
$15.1KCAC
$67KLTV
4.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Natural Killer Cells Therapeutics Market is a resilient opportunity — $1.72B by 2033, compounding at 3.4%.
TAM · 2025$1.32Btoday
TAM · 2033$1.72Bforecast
CAGR3.4%2027–2033
Cumulative$13.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.72BTotal addressable market
SAM$685MServiceable available market
SOM$135MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.4% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.72BLarge & growingTAM by 2033 at 3.4% CAGR
$685MServiceable nowreachable with today’s model
$135MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.34BBear2.2% CAGR
$1.72BBase3.4% CAGR
$2.20BBull4.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Natural Killer Cells Therapeutics Market — a $1.66B market by 2033. Plan: grow share from 6.3% to 11.1%.
Market size · 2033$1.66Btotal addressable
Market CAGR10.0%2027–2033
Target share11.1%from 6.3% today
Revenue ambition$184Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.3% | 11.1% | Behind |
| Revenue | $107M | $184M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 29.7% | 41.1% | At risk |
| Customer retention | 84.7% | 95.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Indication capability
A defensible second engine — invest in Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $24M capacity & capability investment
- Greenlight bolt-on M&A in Indication
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Natural Killer Cells Therapeutics Market conversation — a $5.53B market you can size, segment and defend in minutes.
Market size · 2033$5.53Btotal opportunity
Growth5.8%CAGR to 2033
Addressable buyers1,679+accounts in scope
Typical ROI6.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.7×return on cost, year one
< 2 mopayback period
$56K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Fate Therapeutics Inc.Nkarta Therapeutics Inc.Genocea Biosciences Inc.Cellularity Inc.Kiadis Pharma (Sanofi)Gilead SciencesInc. (Kite Pharma)ImmunityBio Inc.+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Natural Killer Cells Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Natural Killer Cells Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Nucleic Acid-Based Multiplex Assays Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportTumor Microwave Ablation Systems Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportTumor Radiofrequency Ablation Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportMedical Practice Management (PMS) Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportAnti-Obesity Prescription Drugs Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportBrilinta Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportTicagrelor Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportOral Antiseptic Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCoenzyme A Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportImmunocytokines Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportChildhood Vaccines Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportGlioblastoma Treatment Drugs Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.